This content is for packaging education. We do not sell any regulated products.

Many teams chase “the next cannabinoid,” then find the demand story changes by channel and format. That mistake creates wrong SKUs, wrong inventory, and weak repeat purchase.

In 2026, growth is rarely driven by a single molecule. THC still anchors most intoxicating sales, CBD often becomes a formula component, and minor cannabinoids grow through effects-driven positioning and new product forms. See packaging options that protect consistency across cannabinoids and formats.

A clear answer starts with definitions. The word “growth” can mean units, revenue, or share. It can also mean dispensary cannabis or hemp-derived intoxicating products. This article locks the scope first, then maps which cannabinoids tend to drive which type of growth.

What does “growth” mean in this article, and why does scope change the answer?

Many claims sound confident, but they mix different markets and metrics. That confusion makes THC, CBD, and minor cannabinoids look like they “win” at the same time.

This article treats “growth” as a scoped comparison by channel and by metric, because units and dollars can move in opposite directions.

A scope checklist that prevents category math errors

A useful comparison states three inputs. The first input is the channel. Dispensary sales and hemp-derived intoxicating products can follow different rules and buyer behavior. The second input is the metric. Revenue can rise from price, while units rise from adoption. Those are different stories. The third input is the product layer. Some data describe total cannabis sales, while other data describe “products that reference non-THC cannabinoids” in naming and positioning. A team should also note market maturity. Mature markets often show price compression, which changes the meaning of dollar growth. Once the scope is fixed, the result becomes clearer: THC usually anchors the main intoxicating base, while CBD and minor cannabinoids often show their strongest growth signals inside wellness-style categories and effects-driven marketing strategies.

Scope item	Options	Why it matters
Channel	Dispensary vs hemp-derived	Regulation and availability change demand
Metric	Units vs dollars vs share	Price shifts can invert conclusions
Product layer	Total sales vs “cannabinoid-marketed” SKUs	Marketing language changes what is counted

Evidence (Source + Year):
Headset, “Beyond Potency: How Brands Can Stand Out With Effects-Driven Strategies” (methodology notes and cannabinoid-marketing approach) (2025). :contentReference[oaicite:0]{index=0}

Why does THC still dominate, while growth often comes from new forms instead of higher potency?

Many buyers still start with THC, but not every buyer wants higher potency. Mature markets reward products that are easier to use and easier to repeat.

BDSA reported cannabis beverages reached $54.6M in Q1 2025 and grew +15% versus Q1 2024, while holding about 0.9% dollar share of total cannabis sales and 6% of edible sales.

THC growth is often “format-led,” not “percent-led”

THC is still the most recognized intoxicating driver, but the growth mechanism can shift. A beverage or microdose edible can attract a consumer who avoids high-potency flower or concentrates. That is not a medical claim. It is a shopping behavior pattern that rewards low friction, social use, and controlled servings. BDSA’s beverage data is useful because it shows a small category can grow quickly and still remain a small share. That is a classic “new form” signal: high growth rate, low base, and strong visibility. Teams should treat this as proof that THC-led growth can come from “how THC is delivered,” not only “how strong it is.” A product plan that only raises THC% can miss the consumer segment that wants controlled, repeatable experiences.

THC-led format	What it sells	Why it can grow
Flower / pre-roll	Familiar base	Value shopping and routine use
Vapes	Fast use	Discretion and device preference
Edibles	Measured servings	Controlled intake and convenience
Beverages	Social form	New occasions and low barrier trial

Evidence (Source + Year):
BDSA, “2025 Cannabis Beverage Market” (Q1 2025 $54.6M; +15% YoY; ~0.9% dollar share; ~6% edible share) (2025). :contentReference[oaicite:1]{index=1}

How is CBD changing in 2026: why is it often a formula component rather than the headline?

CBD is not disappearing, but its role is shifting. Many products now sell “an experience,” and CBD becomes one ingredient in a combination.

Headset reported CBD still appears in about 65% of products marketed with non-THC cannabinoids, but its share has declined as other cannabinoids gain momentum.

CBD becomes the “base layer” inside effects-driven positioning

CBD tends to show up where brands want a softer positioning or a balanced story. The key change is that brands and retailers increasingly use effects-based language and cannabinoid combinations, not a single-compound headline. Headset’s analysis describes how effects-driven strategies can attract newer customers and repeat buyers who are less motivated by potency alone. That logic helps explain why CBD remains common but loses share inside the “non-THC cannabinoid-marketed” universe. CBD can function as a familiar anchor, while CBN, CBG, THCV, or CBC become the differentiator. In practice, this means CBD’s growth contribution often shows up as “supporting chemistry” in tinctures, capsules, and edibles that are marketed by experience, not by THC%. For operators, the CBD question becomes: is CBD pulling new buyers, or is CBD helping a product deliver a consistent, repeatable positioning?

CBD use pattern	Typical positioning	What it can improve
CBD-only	Simple and familiar	Clarity for first-time shoppers
CBD + minor cannabinoids	Effects-driven combinations	Differentiation and repeatable story
CBD + THC microdose	Controlled experience	Lower barrier trial vs higher potency

Evidence (Source + Year):
Headset, “Beyond Potency: How Brands Can Stand Out With Effects-Driven Strategies” (CBD ~65% presence within non-THC cannabinoid-marketed products; share declining) (2025). :contentReference[oaicite:2]{index=2}

Why do minor cannabinoids look like structural growth instead of a short-term hype cycle?

Minor cannabinoids can look like “buzzwords,” but multiple datasets suggest real expansion. A market can grow even when consumer understanding is still early.

Grand View Research estimated the U.S. minor cannabinoids market at $11.5B in 2023 and forecast 15.0% CAGR from 2024 to 2030, while BDSA materials highlight retail tracking interest in CBG, THCV, and CBN.

Two layers of proof: market sizing plus retail examples

Structural growth is easier to argue when two types of evidence align. Market sizing shows that investment and production are expanding, which supports availability. Retail tracking examples show where brands are placing these cannabinoids into products that consumers can actually buy. Grand View Research provides the macro layer with a 15.0% CAGR forecast for the U.S. minor cannabinoids market from 2024 to 2030. BDSA “Quick Hits” slides add the micro layer by naming examples of brands using CBG, THCV, and CBN in product concepts. Together, these sources support a cautious conclusion: minor cannabinoids are becoming a repeatable way to segment products by “what the buyer wants,” not only “how strong it is.” The growth driver is often the label and the promise structure, not a single molecule acting alone.

Minor cannabinoid (examples)	Where it often appears	What the label usually signals	Main risk
CBN	Edibles, tinctures	Nighttime / calm language	Overpromising outcomes
CBG	Gummies, wellness forms	Daytime / focus language	Inconsistent naming rules
THCV	Edibles, beverages	“Different feel” positioning	Weak comparability across SKUs

Evidence (Source + Year):
Grand View Research, “U.S. Minor Cannabinoids Market” (2023 size; 2024–2030 CAGR 15.0%) (2024). :contentReference[oaicite:3]{index=3}
BDSA, “Cannabis Infused Foods and Beverages” (Quick Hits: minor cannabinoids; examples CBG/THCV/CBN) (2022). :contentReference[oaicite:4]{index=4}

Why is 2026 growth driven by repeatable experiences more than any single cannabinoid?

Many shoppers do not buy “a molecule.” Most shoppers buy a promise they can repeat, at a price they accept, in a form that fits their life.

Headset described effects-based marketing as a path to attract new customers and convert them into loyal return buyers, with brands highlighting specific cannabinoid combinations.

Repeat purchase is the real test of “what drives growth”

Growth becomes durable when a product can be bought again with confidence. That typically requires three things: clear expectations, consistent delivery, and easy shopping. Effects-driven positioning can improve all three when brands communicate cannabinoid combinations in a stable way. Headset’s analysis points to effects-based marketing and highlights how some brands build portfolios around combinations and clear experience expectations. This helps explain why minor cannabinoids can “drive growth” without replacing THC. THC can still anchor intoxication demand, but combinations can create product families that feel more predictable. This also explains why CBD remains present. CBD can be part of a repeatable “balance” story even when it is not the headline. In 2026, the winning pattern is often not “THC vs CBD vs minor.” The winning pattern is a portfolio that matches cannabinoids to occasions and keeps that experience consistent across batches.

Growth goal	What usually helps	How cannabinoids are used
New customer trial	Low friction, clear label	THC microdose, simple combos
Repeat purchase	Predictable experience	Effects-driven combinations
Premium pricing	Differentiation buyers understand	Minor cannabinoids + tight positioning

Evidence (Source + Year):
Headset, “Beyond Potency: How Brands Can Stand Out With Effects-Driven Strategies” (effects-based marketing and cannabinoid combinations) (2025). :contentReference[oaicite:5]{index=5}

What does all of this signal for packaging: what must stay consistent across THC, CBD, and minor cannabinoids?

Many brands improve formulas but lose repeat purchase because packaging fails. A consumer blames the product when the real issue is stability, leakage, or shelf drift.

As a flexible packaging manufacturer, we focus on keeping the delivered experience consistent by protecting barrier performance, seal integrity, and readable labeling across batches and channels.

Packaging protects the “repeatable experience” that drives growth

Packaging does not create demand, but packaging protects demand. When a product strategy moves toward effects-driven combinations, the tolerance for inconsistency drops. A label that says “CBN + CBD” becomes a promise. A seal leak, odor loss, or scuff that destroys compliance readability can break that promise, even if the formula is correct. This matters across formats. Vapes and concentrates rely on clean presentation and reliable closures. Edibles and beverages rely on stable storage and clear information. Tinctures and capsules rely on long-term protection and clean, readable packaging surfaces. We treat packaging as part of “experience repeatability.” That means stable materials, controlled sealing windows, and print durability that stays legible after handling. Explore packaging structures that reduce leakage, odor loss, and label damage during distribution.

Risk to repeatability	What it looks like	Packaging control point
Barrier drift	Odor loss, staleness cues	Film selection and laminate control
Seal failure	Leaks, returns, distrust	Seal window and contamination control
Information loss	Unreadable compliance text	Print protection and scuff resistance

Evidence (Source + Year):
Headset, “Beyond Potency: How Brands Can Stand Out With Effects-Driven Strategies” (effects-driven products rely on clear expectations and trust) (2025). :contentReference[oaicite:6]{index=6}

How can a brand verify what is driving growth in its own data without guessing?

Market reports are useful, but each brand has its own buyer mix. A simple internal test can show whether THC, CBD, or minor cannabinoids are driving trial and repeat.

Headset described how cannabinoid-forward products can outperform in sales within certain portfolios, which supports measuring growth at the SKU level rather than debating labels.

A repeatable “SKU scoreboard” for cannabinoid-driven growth

A brand can run a clean internal study without advanced analytics. The brand can label each SKU by dominant positioning: THC-only, CBD-forward, or minor-cannabinoid-forward, plus the format: flower, vape, edible, beverage, or tincture/capsule. The brand can then track five measures per SKU: unit velocity, revenue per SKU, promotion share, repeat proxy, and complaint rate. Units show adoption. Revenue shows value capture. Promotion share shows whether demand is real or discounted. Repeat proxy shows whether the product is becoming routine. Complaint rate shows whether the promise is failing at the customer level. The brand can also separate “trial growth” from “repeat growth” by comparing first-time baskets and return baskets where possible. This approach turns the 2026 question into operational learning.

Metric	What it tells	Common action
Unit velocity	What wins without hype	Expand pack sizes and distribution
Repeat proxy	What becomes routine	Standardize formula + messaging
Complaint rate	Where trust breaks	Fix spec, packaging, or labeling

Evidence (Source + Year):
Headset, “Beyond Potency: How Brands Can Stand Out With Effects-Driven Strategies” (portfolio example and cannabinoid-marketed products linked to performance) (2025). :contentReference[oaicite:7]{index=7}

Conclusion

THC anchors the biggest base, CBD often supports combination formulas, and minor cannabinoids grow through effects-driven positioning and new forms. The growth winner is repeatable experience, not a single molecule. Contact us to protect product consistency with the right packaging system.

Get Packaging Recommendations for Cannabinoid-Focused SKUs

This content is for packaging education. We do not sell any regulated products.

---

About Us

Brand: Jinyi
Slogan: From Film to Finished—Done Right.
Website: https://jinyipackage.com/

Our Mission:
JINYI is a source manufacturer specializing in custom flexible packaging. We aim to deliver reliable, practical, production-ready packaging systems so brands spend less time aligning details and get more predictable quality, lead times, and real-world performance.

About Us:
JINYI is a source manufacturer specializing in custom flexible packaging solutions, with over 15 years of production experience serving food, snack, pet food, and daily consumer brands.

We operate a standardized manufacturing facility equipped with multiple gravure printing lines as well as advanced HP digital printing systems, allowing us to support both stable large-volume orders and flexible short runs with consistent quality.

From material selection to finished pouches, we focus on process control, repeatability, and real-world performance. Our goal is to help brands reduce communication costs, achieve predictable quality, and ensure packaging performs reliably on shelf, in transit, and at end use.

---

FAQ

1) Is THC still the main driver of cannabis product growth in 2026?
THC still anchors most intoxicating demand, but growth can be format-led, such as beverages and microdose edibles, rather than only higher potency.

2) Does CBD still matter if minor cannabinoids are trending?
CBD still appears in many cannabinoid-marketed products, but it often shifts into a supporting role inside combinations and effects-driven positioning.

3) Which minor cannabinoids show the strongest momentum in effects-driven marketing?
Headset reported growth in the presence of cannabinoids like CBN, CBG, THCV, and CBC within products marketed around non-THC cannabinoids.

4) How should a brand measure “what drives growth” without guessing?
A brand can label SKUs by positioning (THC-only, CBD-forward, minor-forward), then track units, repeat proxy, promotion share, and complaint rate by format.

5) Why can units rise while revenue falls in mature markets?
Price compression can reduce dollars even when more units sell. That is why “growth” must be defined as units, dollars, or share before making conclusions.